In RET-fusion positive NSCLC patients who had progressed on prior chemotherapy, treatment with the RET kinase inhibitors, vandetanib or carbozantinib, results with partial responses in three patients [26, 27]. Here, RET is linked to non-small cell lung carcinoma.